Clinical trials: Cervical Intraepithelial Neoplasia Grade 2
Cervical Cancer, Cervical Intraepithelial Neoplasia Grade 2
Photodynamic Therapy Using Lutetium Texaphyrin in Treating Patients With Cervical Intraepithelial Neoplasia
Phase I trial to study the effectiveness of photodynamic therapy with lutetium texaphyrin in treating patients who have cervical intraepithelial neoplasia.
- Conditions
- Cervical Cancer, Cervical Intraepithelial Neoplasia Grade 2, Cervical Intraepithelial Neoplasia Grade 3
- Trial name
- NCT00005808
- Testing
- motexafin lutetium, photodynamic therapy, loop electrosurgical excision procedure
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- National Cancer Institute (NCI)
Cervical Cancer, High Grade Sil
Screening Study for Cervical Pre-cancer and Cancer Prevention in South African Women.
Nearly 8 000 new cervical cancer cases are diagnosed in South Africa per year; many are still undiagnosed and about 50% of diagnosed cases succumb per year.
- Conditions
- Cervical Cancer, High Grade Sil, CIN2
- Trial name
- DiaVACCS (NCT02956031)
- Testing
- Screening, Colposcopy, LLETZ
- Where
- South Africa
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- University of Pretoria
Cervical Intraepithelial Neoplasia Grade I/ II/ III (CIN I/II/III), Human Papillomavirus (HPV) Infections
A Study to Assess the Reduction of Human Papillomavirus (HPV) Viral Infectivity and Transmission in HPV-Positive Women After Vaccination With 9vHPV (RIFT-HPV)
This is a non-randomized, open label study to assess the reduction of Human Papillomavirus (HPV) infectivity and transmission in women positive for HPV16 and/or 18 in a cervical, oral and anal sample and vaccinated with…
- Conditions
- Cervical Intraepithelial Neoplasia Grade I/ II/ III (CIN I/II/III), Human Papillomavirus (HPV) Infections, High-risk HPV, HPV-16/ 18
- Trial name
- RIFT-HPV (NCT05334706)
- Testing
- Nonavalent HPV vaccine (9vHPV/Gardasil-9™).
- Where
- Spain
- Volunteers
- 69 people
- Sponsor
- Miquel Angel Pavon Ribas
HPV Infection
Assessing Administration of pBI-11 Via Electroporation for the Treatment of Patients With HPV16/18+
This research is being done to test the safety and feasibility of an investigational DNA vaccine called pBI-11 and to find out what effects, if any, it has on women with persistent human papillomavirus 16 (HPV16+) and/or human…
- Trial name
- NCT06210854
- Testing
- pBI-11 (3 doses), pBI-11 (1 dose)
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Human Papillomavirus (HPV)
Fourth Dose of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + EP in Adult Females Previously Vaccinated With Three Doses of VGX-3100
DNA vaccines, which are small pieces of DNA also known as plasmids, have several advantages over traditional vaccines such as live attenuated virus and recombinant protein-based vaccines.
- Trial name
- NCT01188850
- Testing
- VGX-3100
- Where
- 3 sites in United States, Puerto Rico
- Volunteers
- 14 people
- Sponsor
- Inovio Pharmaceuticals
Cervical Intraepithelial Neoplasia-II, High Risk Human Papillomavirus
Effect of Honey For CIN II
The following hypothesis is tested: Medical grade honey in CIN II causes a higher clearance of the hr-HPV virus and an increase in the normalization of CIN II lesions compared to expectant management.
- Trial name
- HoneyForCINII (NCT06219018)
- Testing
- Medical grade honey formulation (MGH) (L-Mesitran®)
- Where
- 2 sites in Netherlands
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Zuyderland Medisch Centrum
CIN2
Conservative Management of CIN2 Lesions and Biomarkers Evaluation
Prospective study including women aged 25-45 years, adherent to the cervical screening program of four different centers of the Veneto region, with a diagnosis of CIN2 lesion.
- Trial name
- NCT04687267
- Where
- 4 sites in Italy
- Volunteers
- 319 people
- Sponsor
- Istituto Oncologico Veneto IRCCS
I) Atypical Squamous Cells of Undetermined Significance (ASC-US), II) Atypical Glandular Cells of Uncertain Significance (AGUS)
Comparison Between Liquid-Based Cytology And Molecular Screening For Detecting Precursor Lesions and Cervical Cancer
This study compares how effective is the molecular screening (a blood test) using Pap smear as reference, that is, a comparison of these tests abilities to detect precursor lesions and cervical cancer among women of an open…
- Conditions
- I) Atypical Squamous Cells of Undetermined Significance (ASC-US), II) Atypical Glandular Cells of Uncertain Significance (AGUS), III) Cervical Intraepithelial Neoplasia (CIN), CIN-1, CIN-2, CIN-3, IV) Low-grade Squamous Intraepithelial Lesion (LSIL)
- Trial name
- NCT07480902
- Testing
- Physical examination, Liquid-based cytology, Molecular screening
- Where
- Mexico
- Volunteers
- 558 people, healthy volunteers welcome
- Sponsor
- Timser SAPI de CV
Cervical Cancer, Genital Wart
A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females
This study is designed to evaluate the vaccine efficacy, immunogenicity and safety of the 4-valent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 18-45…
- Conditions
- Cervical Cancer, Genital Wart, CIN1, CIN2
- Trial name
- NCT05584332
- Testing
- Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine (Hansenula Polymorpha)
- Where
- China
- Volunteers
- 3,131 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
High Grade Cervical Intraepithelial Neoplasia
An Exploratory Safety and Immunogenicity Study of HPV16+ Immunotherapy VB10.16 in Women With HSIL; CIN 2/3)
This is an exploratory, open, prospective multi-centre study of VB10.16 immunotherapy in patients with high grade HPV16+ Cervical Intraepithelial Neoplasia (HSIL; CIN2/3).
- Trial name
- NCT02529930
- Testing
- VB10.16 Immunotherapy (DNA vaccine)
- Where
- 4 sites in Germany
- Volunteers
- 34 people
- Sponsor
- Nykode Therapeutics ASA
Cervical Intraepithelial Neoplasia Grade 2 (CIN2)
RWS of PDT for CIN 2
This is a prospective, observational, multicenter real-world study designed to evaluate the effectiveness and safety of photodynamic therapy (PDT) in women with cervical intraepithelial neoplasia grade 2 (CIN2).
- Trial name
- Lumiteg-R (NCT07885566)
- Testing
- Hexaminolevulinate (HAL)
- Volunteers
- 1,000 people
- Sponsor
- Tongji Hospital
Cervical Intraepithelial Neoplasia Grade 2, DNA Methylation
The Role of FAM19A4 and Hsa-mir-124 Methylation in Predicting Prognosis of Untreated Cervical Intraepithelial Neoplasia 2 (CIN 2)
High-risk precancerous cervical lesions are divided into stage 2 and 3 cervical intraepithelial neoplasia (CIN 2 and 3). CIN 3 represents a direct pre-stage of invasive cancer, has a high rate of progression and a high degree of…
- Trial name
- NCT05624827
- Testing
- Testing DNA methylation test for predicting prognosis of untreated CIN 2
- Where
- Slovenia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University Medical Centre Maribor
Uterine Cervical Dysplasia
A Study of Amolimogene (ZYC101a) in Patients With High Grade Cervical Intraepithelial Lesions of the Uterine Cervix
The purpose of this study is to evaluate the efficacy and safety of amolimogene, in the treatment of patients with high-grade cervical intraepithelial lesions of the uterine cervix.
- Trial name
- NCT00264732
- Testing
- Amolimogene
- Where
- 26 sites in United States
- Volunteers
- 251 people
- Sponsor
- Eisai Inc.
Cervical Intraepithelial Neoplasia Grade 2/3, Cervical Lesion
Accurate Screening and Prevention of Cervical Lesions-- Development of Accurate Screening Methods for Cervical Lesions
The goal of this observational study is to compare the accuracy and sensitivity of High-throughput human papilloma virus(HPV) typing and integrated assays with routine screening protocols (Cobas HPV test combined with thinprep…
- Trial name
- NCT05851079
- Testing
- TCT test, Vaginoscopy, High throughput HPV typing and integration detection methods
- Where
- China
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- Women's Hospital School Of Medicine Zhejiang University
Magnetic Resonance Imaging Examination
Clinical Value of the MRI Combined With SCC-Ag for the Diagnosis of HSIL (CIN 2/3)
The study aimed to identify the clinical value of Magnetic Resonance Imaging examination (MRI)combined with serum squamous cells carcinoma antigen (SCC-Ag) in women with high-grade squamous intraepithelial lesion (cervical…
- Trial name
- NCT05487209
- Testing
- MRI,SCC-Ag
- Where
- China
- Volunteers
- 186 people
- Sponsor
- Second Affiliated Hospital of Wenzhou Medical University
HIV-1 Infection
HPV Test-and-Treat-Strategy Versus Cytology-based Strategy for Prevention of CIN2+ in HIV-Infected Women
Women sometimes develop cancer in an area called the cervix, which is the opening to the uterus, or womb. Women who have HIV are more likely to get this kind of cancer than women who do not have HIV.
- Trial name
- NCT01315353
- Testing
- Cervical Cryotherapy, Loop Electrosurgical Excision Procedure (LEEP)
- Where
- 13 sites in Botswana, Haiti and 5 more
- Volunteers
- 467 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Cervical Cancer, CIN2
Acceptability and Feasibility of Combination Treatment for Cervical Precancer Among South African Women Living With HIV
The purpose of this study is to explore whether an anti-cancer medication (5-fluorouracil cream) placed in the vagina after a surgical excision procedure is an acceptable and useful form of treatment for cervical precancer among…
- Conditions
- Cervical Cancer, CIN2, CIN3, Human Immunodeficiency Virus
- Trial name
- ACT 2 (NCT05413811)
- Testing
- 5 Fluorouracil (5 FU) Cream
- Where
- South Africa
- Volunteers
- 180 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Cervical Intraepithelial Neoplasia Grade 2, Papillomavirus Infections
ALA-PDT in Patients With CIN2 in p16-positivity and High-risk HPV Infection
Efficacy and Safety of ALA-PDT in patients with cervical intraepithelial neoplasia grade 2 (CIN2) in p16-positivity and high-risk HPV infection.
- Conditions
- Cervical Intraepithelial Neoplasia Grade 2, Papillomavirus Infections, p16 Protein
- Trial name
- NCT06439433
- Testing
- Aminolaevulinic acid (500-mg bottle), Aminolaevulinic acid (750-mg bottle)
- Where
- 5 sites in China
- Volunteers
- 119 people
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Human Papillomavirus Type 16, Cervical Intraepithelial Neoplasia Grade II
HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia
The primary goal of this phase I open label study is to determine the safety and tolerability of pNGVL4aCRTE6E7L2 DNA vaccine, as administered by intramuscular (IM) injection with TriGrid™ electroporation to both HIV- or HIV+…
- Conditions
- Human Papillomavirus Type 16, Cervical Intraepithelial Neoplasia Grade II, Cervical Intraepithelial Neoplasia, Grade III
- Trial name
- NCT04131413
- Testing
- pNGVL4aCRTE6E7L2
- Where
- 2 sites in United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Cervix Cancer, Cervix Intraepithelial Neoplasia Grade 3
Pharmacokinetics of Intravaginal, Self-administered Artesunate Vaginal Pessaries Among Women in Kenya
This study investigates the pharmacokinetics of Artesunate (AS) and dihydroartemisinin (DHA), the active metabolite of Artesunate, following intravaginal use at the dosing and frequency being studied for cervical precancer…
- Conditions
- Cervix Cancer, Cervix Intraepithelial Neoplasia Grade 3, Cervix; Intraepithelial Neoplasia, Grade I, Cervix; Intraepithelial Neoplasia, Grade II
- Trial name
- NCT06263582
- Testing
- Artesunate pessary, blood draws for pharmacokinetics of the study drug
- Where
- Kenya
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- UNC Lineberger Comprehensive Cancer Center